AXIM Biotechnologies(AXIM)
$0.00-0.00 (-0.32%)
AXIM
AXIM Biotechnologies financials statements
$0.00
At close:-0.00 (-0.32%)
AXIM Biotechnologies (AXIM) Ratios
151 Followers
AXIM Biotechnologies Ratios
AXIM's free cash flow for Q2 2026 was $-8.97K. For the 2026 fiscal year, AXIM's free cash flow was increased by $5.00 and operating cash flow was $-8.97K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | 0.03 | 0.03 | 0.25 |
| Quick Ratio | 0.00 | 0.00 | 0.03 | 0.03 | 0.25 |
| Cash Ratio | 0.00 | 0.00 | 0.03 | 0.01 | 0.18 |
| Solvency Ratio | -0.04 | -0.22 | -0.65 | -0.61 | -1.88 |
| Operating Cash Flow Ratio | -0.11 | -0.13 | -0.17 | -0.60 | -0.96 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -11.04 | 0.00 | 0.00 | -1.54 |
| Net Current Asset Value | $ -14.24M | $ -13.87M | $ -11.62M | $ -8.93M | $ -7.03M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.71 | 1.93 | 1.43 | 1.34 | 1.26 |
| Debt-to-Equity Ratio | -0.68 | -0.64 | -0.77 | -1.17 | -2.87 |
| Debt-to-Capital Ratio | -2.17 | -1.76 | -3.35 | 6.75 | 1.53 |
| Long-Term Debt-to-Capital Ratio | -2.17 | -1.66 | -2.84 | 6.89 | 1.86 |
| Financial Leverage Ratio | -0.25 | -0.33 | -0.54 | -0.87 | -2.28 |
| Debt Service Coverage Ratio | -2.61 | -3.42 | -5.34 | -2.10 | -5.58 |
| Interest Coverage Ratio | -3.86 | -2.77 | -2.28 | -2.48 | -10.74 |
| Debt to Market Cap | 2.14 | 10.86 | 1.31 | 1.23 | 0.12 |
| Interest Debt Per Share | 0.02 | 0.02 | 0.03 | 0.05 | 0.06 |
| Net Debt to EBITDA | -8.72 | -2.72 | -0.89 | -1.43 | -0.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | -524.10% | 100.00% | -4701.42% | 100.00% |
| EBIT Margin | 0.00% | -4082.30% | -17346.32% | -49200.36% | -25700.44% |
| EBITDA Margin | 0.00% | -3468.61% | -16265.75% | -44398.94% | -21775.28% |
| Operating Profit Margin | 0.00% | -2502.31% | -6960.98% | -52425.60% | -13207.09% |
| Pretax Profit Margin | 0.00% | -4985.19% | -20394.96% | -70343.09% | -26503.98% |
| Net Profit Margin | 0.00% | -4985.19% | -20394.96% | -67120.74% | -27320.76% |
| Continuous Operations Profit Margin | 0.00% | -4985.19% | -20394.96% | -70343.09% | -26503.98% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 95.42% | 103.08% |
| EBT Per EBIT | 79.04% | 199.22% | 292.99% | 134.18% | 200.68% |
| Return on Assets (ROA) | -36.25% | -101.89% | -195.55% | -141.43% | -310.29% |
| Return on Equity (ROE) | 9.18% | 33.71% | 105.26% | 123.45% | 706.45% |
| Return on Capital Employed (ROCE) | 41.24% | 53.18% | 148.14% | -567.73% | -291.16% |
| Return on Invested Capital (ROIC) | 41.24% | 55.79% | 156.12% | -554.34% | -180.91% |
| Return on Tangible Assets | -1469.05% | -1423.43% | -1530.61% | -2675.99% | -1758.07% |
| Earnings Yield | -28.63% | -579.71% | -186.30% | -129.97% | -29.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.25 | 0.25 | 0.00 | 0.32 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.30 | 0.11 | 0.08 | 0.31 |
| Asset Turnover | 0.00 | 0.02 | 0.01 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | -0.01 | -0.01 | -0.00 | -0.04 |
| Cash Conversion Cycle | -1487.42 | -1482.43 | 0.00 | -1127.44 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1487.42 | 1482.43 | 0.00 | 1127.44 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.01 | -0.02 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.01 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -300.86 | 0.00 | -234.71 | -49.25 |
| Capital Expenditure Coverage Ratio | 0.00 | -300.86 | 0.00 | -234.71 | -49.25 |
| Operating Cash Flow Coverage Ratio | -0.09 | -0.13 | -0.17 | -0.36 | -0.37 |
| Operating Cash Flow to Sales Ratio | 0.00 | -12.14 | -26.08 | -230.35 | -41.13 |
| Free Cash Flow Yield | -18.84% | -141.59% | -23.82% | -44.79% | -4.45% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.45 | -0.17 | -0.54 | -0.77 | -3.45 |
| Price-to-Sales (P/S) Ratio | 0.00 | 8.60 | 109.47 | 516.45 | 942.06 |
| Price-to-Book (P/B) Ratio | -0.32 | -0.06 | -0.57 | -0.95 | -24.36 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.31 | -0.71 | -4.20 | -2.23 | -22.45 |
| Price-to-Operating Cash Flow Ratio | -5.31 | -0.71 | -4.20 | -2.24 | -22.90 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | 0.00 | 0.32 | 0.01 | -0.03 |
| Enterprise Value Multiple | -12.80 | -2.96 | -1.57 | -2.59 | -4.80 |
| Enterprise Value | 11.42M | 7.25M | 10.06M | 10.20M | 63.22M |
| EV to EBITDA | -12.80 | -2.96 | -1.57 | -2.59 | -4.80 |
| EV to Sales | 0.00 | 102.84 | 254.68 | 1149.40 | 1045.70 |
| EV to Free Cash Flow | -16.65 | -8.45 | -9.77 | -4.97 | -24.92 |
| EV to Operating Cash Flow | -16.65 | -8.47 | -9.77 | -4.99 | -25.42 |
| Tangible Book Value Per Share | -0.04 | -0.04 | -0.05 | -0.05 | -0.05 |
| Shareholders’ Equity Per Share | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.01 | -0.04 | -0.04 | -0.13 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.95 | 1.03 |
| Interest Burden | 0.79 | 1.22 | 1.18 | 1.43 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.57 | 3.18 | 17.32 | 4.71 |
| SG&A to Revenue | 0.00 | 19.22 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 5.00 | 124.79 | 18.92 |
| Income Quality | 0.66 | 0.24 | 0.13 | 0.33 | 0.16 |
Currency in USD
